| D7.2 | | MU | 28.02.2023 |
| D6.1 | Initial Training Plan and CDE Plan | MU | 30.06.2023 |
| D7.1 | Data Management Plan | MU | 30.06.2023 |
| D1.1 | Report on Research and Exploitation Potential and Market Analysis | NII SAS | 31.12.2023 |
| D4.1 | Tau biomarker identification in CFS and blood | NII SAS | 31.12.2023 |
| D5.3 | Plan of the Communication Campaign | ICRC | 31.12.2023 |
| D1.2 | Preliminary Joint R&I Strategy | MU + NII SAS | 30.09.2024 |
| D4.6 | Validation of low input microRNA sequencing protocol | MDX | 31.10.2024 |
| D4.2 | Optimized protocol of the purfication and selective phosphorylation of selected Tau fragments prepared recombinantly and Molecular basis of ApoE oligomerization and aggregation | MU | 31.12.2024 |
| D6.2 | Interim Training and CDE Report and Plan | MU | 31.12.2024 |
| D4.4 | Assigned solution NMR spectra of the selected Tau fragments | MU - LF | 31.08.2025 |
| D1.4 | Evaluation Report by the EAB | MU | 31.12.2025 |
| D3.2 | Technology Transfer Framework | MU | 31.12.2025 |
| D4.3 | Novel tau species in the CSF and blood and in the medium of iPSCs and Tau assay development | MU | 31.12.2025 |
| D5.1 | Report on the AD cohorts | ICRC | 31.12.2025 |
| D4.5 | Structural analyses of the selected tau biomarkers and validations of assays and new biomarkers | MU | 31.10.2026 |
| D4.7 | Identification and validation of microRNA biomarkers for AD | MDX | 31.10.2026 |
| D1.3 | Final Joint R&I Strategy and Report on Business/User Networking | MU | 31.12.2026 |
| D2.1 | Final Research Plans and Findings of Feasibility Studies | MU + NII SAS | 31.12.2026 |
| D3.1 | Final Investment Plans and Findings of Patentability Studies | BIOVENDOR | 31.12.2026 |
| D5.2 | Harmonisation of recruitment and diagnostics method and Report on Non-pharmacological Interventions | ICRC | 31.12.2026 |
| D5.4 | Summary of the Communication Campaign | ICRC | 31.12.2026 |
| D6.3 | Final Training Report and Scientific Report on Industrial PhDs, CDE Plan for post-project period | MU | 31.12.2026 |
